Which has better valuation & earnings, CRON or ACIU?

Cronos Group has higher revenue and earnings than AC Immune. AC Immune is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cronos Group $146.59M 7.21 -$9.45M $0.01 283.50 AC Immune $3.70M 69.97 -$85.03M -$0.82 N/A

Is CRON or ACIU more profitable?

Cronos Group has a net margin of -1.14% compared to AC Immune's net margin of -1,788.02%. Cronos Group's return on equity of -1.26% beat AC Immune's return on equity. Company Net Margins Return on Equity Return on Assets Cronos Group -1.14% -1.26% -1.20% AC Immune -1,788.02% -125.26% -40.85%

Which has higher earnings and valuation, ACIU or BIOA?

BioAge Labs has higher revenue and earnings than AC Immune. BioAge Labs is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AC Immune $3.70M 69.97 -$85.03M -$0.82 N/A BioAge Labs $10.32M 102.56 -$80.61M -$2.40 N/A

Is ACIU or BIOA more profitable?

BioAge Labs has a net margin of -871.75% compared to AC Immune's net margin of -1,788.02%. BioAge Labs' return on equity of -29.40% beat AC Immune's return on equity. Company Net Margins Return on Equity Return on Assets AC Immune -1,788.02% -125.26% -40.85% BioAge Labs -871.75% -29.40% -27.26%

Is ACIU or REPL more profitable?

Replimune Group has a net margin of 0.00% compared to AC Immune's net margin of -1,788.02%. Replimune Group's return on equity of -102.69% beat AC Immune's return on equity. Company Net Margins Return on Equity Return on Assets AC Immune -1,788.02% -125.26% -40.85% Replimune Group N/A -102.69% -72.22%

Is ACIU or DBVT more profitable?

AC Immune has a net margin of -1,788.02% compared to DBV Technologies' net margin of -2,895.37%. AC Immune's return on equity of -125.26% beat DBV Technologies' return on equity. Company Net Margins Return on Equity Return on Assets AC Immune -1,788.02% -125.26% -40.85% DBV Technologies -2,895.37% -129.88% -88.84%

AC Immune (ACIU) Competitors

$2.54 -0.02 (-0.59%)

As of 09:49 AM Eastern

Compare

ACIU vs. CRON, BIOA, REPL, AVTX, and DBVT

Should you buy AC Immune stock or one of its competitors? MarketBeat compares AC Immune with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with AC Immune include Cronos Group (CRON), BioAge Labs (BIOA), Replimune Group (REPL), Avalo Therapeutics (AVTX), and DBV Technologies (DBVT). These companies are all part of the "pharmaceutical products" industry.

How does AC Immune compare to Cronos Group?

Cronos Group (NASDAQ:CRON) and AC Immune (NASDAQ:ACIU) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.

Cronos Group presently has a consensus price target of $2.30, indicating a potential downside of 18.87%. AC Immune has a consensus price target of $7.50, indicating a potential upside of 194.70%. Given AC Immune's stronger consensus rating and higher possible upside, analysts clearly believe AC Immune is more favorable than Cronos Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cronos Group	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
AC Immune	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Cronos Group had 3 more articles in the media than AC Immune. MarketBeat recorded 4 mentions for Cronos Group and 1 mentions for AC Immune. AC Immune's average media sentiment score of 1.89 beat Cronos Group's score of 0.91 indicating that AC Immune is being referred to more favorably in the news media.

Company	Overall Sentiment
Cronos Group	Positive
AC Immune	Very Positive

Cronos Group has a beta of 0.89, indicating that its stock price is 11% less volatile than the broader market. Comparatively, AC Immune has a beta of 1.59, indicating that its stock price is 59% more volatile than the broader market.

Cronos Group has a net margin of -1.14% compared to AC Immune's net margin of -1,788.02%. Cronos Group's return on equity of -1.26% beat AC Immune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cronos Group	-1.14%	-1.26%	-1.20%
AC Immune	-1,788.02%	-125.26%	-40.85%

Cronos Group has higher revenue and earnings than AC Immune. AC Immune is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cronos Group	$146.59M	7.21	-$9.45M	$0.01	283.50
AC Immune	$3.70M	69.97	-$85.03M	-$0.82	N/A

8.7% of Cronos Group shares are owned by institutional investors. Comparatively, 51.4% of AC Immune shares are owned by institutional investors. 7.8% of Cronos Group shares are owned by insiders. Comparatively, 4.6% of AC Immune shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Cronos Group beats AC Immune on 9 of the 15 factors compared between the two stocks.

How does AC Immune compare to BioAge Labs?

AC Immune (NASDAQ:ACIU) and BioAge Labs (NASDAQ:BIOA) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, media sentiment, institutional ownership, risk and dividends.

AC Immune currently has a consensus price target of $7.50, suggesting a potential upside of 194.70%. BioAge Labs has a consensus price target of $43.50, suggesting a potential upside of 82.77%. Given AC Immune's higher probable upside, equities research analysts clearly believe AC Immune is more favorable than BioAge Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AC Immune	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, BioAge Labs had 4 more articles in the media than AC Immune. MarketBeat recorded 5 mentions for BioAge Labs and 1 mentions for AC Immune. AC Immune's average media sentiment score of 1.89 beat BioAge Labs' score of 0.47 indicating that AC Immune is being referred to more favorably in the media.

Company	Overall Sentiment
AC Immune	Very Positive
BioAge Labs	Neutral

51.4% of AC Immune shares are owned by institutional investors. 4.6% of AC Immune shares are owned by company insiders. Comparatively, 20.8% of BioAge Labs shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

BioAge Labs has higher revenue and earnings than AC Immune. BioAge Labs is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AC Immune	$3.70M	69.97	-$85.03M	-$0.82	N/A
BioAge Labs	$10.32M	102.56	-$80.61M	-$2.40	N/A

BioAge Labs has a net margin of -871.75% compared to AC Immune's net margin of -1,788.02%. BioAge Labs' return on equity of -29.40% beat AC Immune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AC Immune	-1,788.02%	-125.26%	-40.85%
BioAge Labs	-871.75%	-29.40%	-27.26%

AC Immune has a beta of 1.59, meaning that its stock price is 59% more volatile than the broader market. Comparatively, BioAge Labs has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market.

Summary

BioAge Labs beats AC Immune on 10 of the 16 factors compared between the two stocks.

How does AC Immune compare to Replimune Group?

AC Immune (NASDAQ:ACIU) and Replimune Group (NASDAQ:REPL) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, risk, media sentiment, analyst recommendations and institutional ownership.

In the previous week, Replimune Group had 6 more articles in the media than AC Immune. MarketBeat recorded 7 mentions for Replimune Group and 1 mentions for AC Immune. AC Immune's average media sentiment score of 1.89 beat Replimune Group's score of 1.28 indicating that AC Immune is being referred to more favorably in the media.

Company	Overall Sentiment
AC Immune	Very Positive
Replimune Group	Positive

AC Immune has a beta of 1.59, meaning that its share price is 59% more volatile than the broader market. Comparatively, Replimune Group has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market.

Replimune Group has a net margin of 0.00% compared to AC Immune's net margin of -1,788.02%. Replimune Group's return on equity of -102.69% beat AC Immune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AC Immune	-1,788.02%	-125.26%	-40.85%
Replimune Group	N/A	-102.69%	-72.22%

51.4% of AC Immune shares are owned by institutional investors. Comparatively, 92.5% of Replimune Group shares are owned by institutional investors. 4.6% of AC Immune shares are owned by company insiders. Comparatively, 5.2% of Replimune Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

AC Immune currently has a consensus price target of $7.50, indicating a potential upside of 194.70%. Replimune Group has a consensus price target of $6.00, indicating a potential downside of 47.30%. Given AC Immune's stronger consensus rating and higher probable upside, research analysts clearly believe AC Immune is more favorable than Replimune Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AC Immune	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Replimune Group	3 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80

AC Immune has higher revenue and earnings than Replimune Group. Replimune Group is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AC Immune	$3.70M	69.97	-$85.03M	-$0.82	N/A
Replimune Group	N/A	N/A	-$247.30M	-$3.44	N/A

Summary

AC Immune beats Replimune Group on 10 of the 15 factors compared between the two stocks.

How does AC Immune compare to Avalo Therapeutics?

Avalo Therapeutics (NASDAQ:AVTX) and AC Immune (NASDAQ:ACIU) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

Avalo Therapeutics has a net margin of 0.00% compared to AC Immune's net margin of -1,788.02%. Avalo Therapeutics' return on equity of -97.54% beat AC Immune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalo Therapeutics	N/A	-97.54%	-72.42%
AC Immune	-1,788.02%	-125.26%	-40.85%

Avalo Therapeutics currently has a consensus target price of $46.67, suggesting a potential upside of 151.71%. AC Immune has a consensus target price of $7.50, suggesting a potential upside of 194.70%. Given AC Immune's higher probable upside, analysts clearly believe AC Immune is more favorable than Avalo Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
AC Immune	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

87.1% of Avalo Therapeutics shares are owned by institutional investors. Comparatively, 51.4% of AC Immune shares are owned by institutional investors. 4.5% of Avalo Therapeutics shares are owned by insiders. Comparatively, 4.6% of AC Immune shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Avalo Therapeutics had 6 more articles in the media than AC Immune. MarketBeat recorded 7 mentions for Avalo Therapeutics and 1 mentions for AC Immune. AC Immune's average media sentiment score of 1.89 beat Avalo Therapeutics' score of 0.65 indicating that AC Immune is being referred to more favorably in the news media.

Company	Overall Sentiment
Avalo Therapeutics	Positive
AC Immune	Very Positive

Avalo Therapeutics has a beta of 0.83, suggesting that its stock price is 17% less volatile than the broader market. Comparatively, AC Immune has a beta of 1.59, suggesting that its stock price is 59% more volatile than the broader market.

Avalo Therapeutics has higher earnings, but lower revenue than AC Immune. Avalo Therapeutics is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalo Therapeutics	$60K	16,244.13	-$78.26M	-$5.46	N/A
AC Immune	$3.70M	69.97	-$85.03M	-$0.82	N/A

Summary

Avalo Therapeutics and AC Immune tied by winning 8 of the 16 factors compared between the two stocks.

How does AC Immune compare to DBV Technologies?

AC Immune (NASDAQ:ACIU) and DBV Technologies (NASDAQ:DBVT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, profitability, valuation, risk, institutional ownership and dividends.

AC Immune has higher revenue and earnings than DBV Technologies. DBV Technologies is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AC Immune	$3.70M	69.97	-$85.03M	-$0.82	N/A
DBV Technologies	N/A	N/A	-$146.95M	-$4.46	N/A

AC Immune has a net margin of -1,788.02% compared to DBV Technologies' net margin of -2,895.37%. AC Immune's return on equity of -125.26% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AC Immune	-1,788.02%	-125.26%	-40.85%
DBV Technologies	-2,895.37%	-129.88%	-88.84%

51.4% of AC Immune shares are owned by institutional investors. Comparatively, 71.7% of DBV Technologies shares are owned by institutional investors. 4.6% of AC Immune shares are owned by company insiders. Comparatively, 1.1% of DBV Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

AC Immune has a beta of 1.59, meaning that its share price is 59% more volatile than the broader market. Comparatively, DBV Technologies has a beta of -0.99, meaning that its share price is 199% less volatile than the broader market.

In the previous week, DBV Technologies had 2 more articles in the media than AC Immune. MarketBeat recorded 3 mentions for DBV Technologies and 1 mentions for AC Immune. AC Immune's average media sentiment score of 1.89 beat DBV Technologies' score of 0.63 indicating that AC Immune is being referred to more favorably in the media.

Company	Overall Sentiment
AC Immune	Very Positive
DBV Technologies	Positive

AC Immune currently has a consensus price target of $7.50, suggesting a potential upside of 194.70%. DBV Technologies has a consensus price target of $48.50, suggesting a potential upside of 184.74%. Given AC Immune's higher possible upside, equities analysts clearly believe AC Immune is more favorable than DBV Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AC Immune	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
DBV Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Summary

AC Immune beats DBV Technologies on 11 of the 16 factors compared between the two stocks.

Get AC Immune News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACIU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACIU vs. The Competition

Export

Metric	AC Immune	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$259.02M	$3.62B	$6.83B	$12.17B
Dividend Yield	N/A	2.22%	2.66%	6.11%
P/E Ratio	-3.10	21.75	25.88	24.17
Price / Sales	69.97	332.75	550.12	99.13
Price / Cash	N/A	62.10	29.09	36.93
Price / Book	4.71	8.31	10.76	6.38
Net Income	-$85.03M	$23.92M	$3.58B	$337.00M
7 Day Performance	1.80%	1.93%	1.93%	-0.23%
1 Month Performance	-4.32%	-0.41%	-0.23%	-1.40%
1 Year Performance	26.62%	65.22%	34.40%	27.76%

AC Immune Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACIU AC Immune	2.8334 of 5 stars	$2.55 -0.6%	$7.50 +194.7%	+26.6%	$259.02M	$3.70M	N/A	140	Positive News
CRON Cronos Group	1.3791 of 5 stars	$2.69 +1.3%	$2.30 -14.3%	+47.9%	$1.00B	$146.59M	268.77	450
BIOA BioAge Labs	2.5745 of 5 stars	$22.40 +4.3%	$43.50 +94.2%	N/A	$995.97M	$10.32M	N/A	N/A	Gap Down
REPL Replimune Group	1.9725 of 5 stars	$11.93 +6.7%	$4.88 -59.2%	+24.7%	$990.88M	N/A	N/A	210	Positive News Earnings Report Analyst Upgrade Gap Down
AVTX Avalo Therapeutics	3.399 of 5 stars	$18.23 +6.7%	$46.67 +156.0%	+280.0%	$960.72M	$60K	N/A	40

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ACIU) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AC Immune (ACIU) Competitors

ACIU vs. CRON, BIOA, REPL, AVTX, and DBVT

How does AC Immune compare to Cronos Group?

Summary

How does AC Immune compare to BioAge Labs?

Summary

How does AC Immune compare to Replimune Group?

Summary

How does AC Immune compare to Avalo Therapeutics?

Summary

How does AC Immune compare to DBV Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACIU vs. The Competition

AC Immune Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AC Immune (ACIU) Competitors

ACIU vs. CRON, BIOA, REPL, AVTX, and DBVT

How does AC Immune compare to Cronos Group?

Do analysts recommend CRON or ACIU?

Does the media prefer CRON or ACIU?

Which has more volatility & risk, CRON or ACIU?

Is CRON or ACIU more profitable?

Which has better valuation & earnings, CRON or ACIU?

Do insiders and institutionals believe in CRON or ACIU?

Summary

How does AC Immune compare to BioAge Labs?

Do analysts recommend ACIU or BIOA?

Does the media refer more to ACIU or BIOA?

Do insiders and institutionals hold more shares of ACIU or BIOA?

Which has higher earnings and valuation, ACIU or BIOA?

Is ACIU or BIOA more profitable?

Which has more risk & volatility, ACIU or BIOA?

Summary

How does AC Immune compare to Replimune Group?

Does the media refer more to ACIU or REPL?

Which has more risk and volatility, ACIU or REPL?

Is ACIU or REPL more profitable?

Do insiders & institutionals have more ownership in ACIU or REPL?

Do analysts recommend ACIU or REPL?

Which has preferable earnings and valuation, ACIU or REPL?

Summary

How does AC Immune compare to Avalo Therapeutics?

Is AVTX or ACIU more profitable?

Do analysts recommend AVTX or ACIU?

Do institutionals & insiders hold more shares of AVTX or ACIU?

Does the media refer more to AVTX or ACIU?

Which has more risk and volatility, AVTX or ACIU?

Which has stronger valuation and earnings, AVTX or ACIU?

Summary

How does AC Immune compare to DBV Technologies?

Which has stronger earnings and valuation, ACIU or DBVT?

Is ACIU or DBVT more profitable?

Do institutionals and insiders hold more shares of ACIU or DBVT?

Which has more risk and volatility, ACIU or DBVT?

Does the media refer more to ACIU or DBVT?

Do analysts prefer ACIU or DBVT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACIU vs. The Competition

AC Immune Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools